Table S2 – Free survival rates of disease according to the study variables (in 5 years).

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **n** | Free survival rates **(\*1)****(% in 5 years)** | **P value****(\*2)** |
|  |  |  |  |
| **Histopathology**  |  |  |  |
| Squamous cells carcinoma | 107 | 84,2 | 0,273 |
| Adenocarcinoma/Adenosquamous | 8 | 100,0 |  |
|  |  |  |  |
| **Histological grade** |  |  |  |
| Grade I | 4 | 100,0 | 0,645 |
| Grade II | 47 | 71,6 |  |
| Grade III | 5 | 80,0 |  |
|  |  |  |  |
| **Type of carcinoma** |  |  |  |
| In situ | 50 | 95,4 | < 0,012 |
| Invasive | 65 | 77,4 |  |
|  |  |  |  |
| **Stage (FIGO)** |  |  |  |
| In situ | 50 | 95,4 | 0,001 |
| Stage1 + 2 | 40 | 86,9 |  |
| Stage3 + 4  | 25 | 58,7 |  |
|  |  |  |  |
| **Lymph node metastasis (\*3)** |  |  | 0,155 |
| No  | 107 | 86,6 |  |
| Yes | 8 | 62,5 |  |
|  |  |  |  |
| **Elafin – plasm cell membrane** |  |  |  |
| Negative / 1+ | 64 | 81,4 | 0,185 |
| 2+ / 3+  | 51 | 90,7 |  |
|  |  |  |  |
| **Elafin – nucleus** |  |  |  |
| Negative / 1+ | 98 | 85,7 | 0,649 |
| 2+ / 3+  | 17 | 82,4 |  |
|  |  |  |  |
| **Elafin – cytoplasm** |  |  |  |
| Negative / 1+ | 94 | 83,2 | 0,222 |
| 2+ / 3+  | 21 | 94,4 |  |
|  |  |  |  |

(\*1) Cases considered IVB were excluded from analysis.

(\*2) Log-rank test.

(\*3) Clinical or pathological assessment.

The International Federation of Gynecology and Obstetrics (FIGO)